Mumbai, July 28: Dr Reddy’s Laboratories Ltd plans to file an application with the US Food and Drug Administration (FDA) to start clinical development of DRF 10945, an oral drug for treatment of dyslipidemia, in that country.

At present, the clinical development of the drug is in the first phase in Canada. This is the first time that the company is conducting clinical trials for a new drug compound outside India.

While Dr Reddy’s anti-diabetic drug, which has been licensed to Novo Nordisk, has completed Phase II clinical trials, the anti-cancer compound, DRF 1042, has entered the second phase of trials in India, chairman Anji Reddy said at the company’s annual general meeting in Hyderabad today.

Reddy said the firm has discovered RUS 3108, a drug which will be potentially useful in the treatment of atherosclerosis.